Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPositive phase II results for GSK1838262 reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
GlaxoSmithKline, 10/06/09
GlaxoSmithKline and XenoPort, Inc. announced top–line results from a Phase II clinical trial evaluating GSK1838262/XP13512 in adult patients with neuropathic pain associated with post–herpetic neuralgia who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher. In this double–blind, two–period cross–over study, 3600 mg/day of GSK 1838262 demonstrated a statistically significant improvement over 1200 mg/day of GSK1838262 on the primary endpoint, which was the change from baseline to the end of the treatment period in the 24–hour average pain intensity score.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Primary endpoint reached in Active Biotechs TASQ Phase II clinical trial in prostate cancer patients
Active Biotech, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor